Given the evolving metabolic profile of CF patients, consideration of newer T2DM therapies such as SGLT2 inhibitors (e.g., dapagliflozin), as used in our study, may also be warranted to optimise metabolic and cardiovascular outcomes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.